Skba Capital Management LLC Has $13.73 Million Holdings in Kenvue Inc. $KVUE

Skba Capital Management LLC raised its holdings in Kenvue Inc. (NYSE:KVUE) by 24.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 845,775 shares of the company’s stock after buying an additional 163,900 shares during the period. Kenvue accounts for about 1.9% of Skba Capital Management LLC’s portfolio, making the stock its 22nd largest holding. Skba Capital Management LLC’s holdings in Kenvue were worth $13,727,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of KVUE. AlphaCore Capital LLC lifted its holdings in Kenvue by 9.9% during the 2nd quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock valued at $111,000 after purchasing an additional 476 shares during the last quarter. Empirical Finance LLC grew its stake in Kenvue by 1.8% in the 2nd quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after buying an additional 491 shares during the last quarter. J.W. Cole Advisors Inc. raised its holdings in Kenvue by 3.8% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock valued at $324,000 after acquiring an additional 574 shares during the period. Spire Wealth Management lifted its position in Kenvue by 13.5% during the second quarter. Spire Wealth Management now owns 4,863 shares of the company’s stock worth $102,000 after acquiring an additional 580 shares during the last quarter. Finally, Versor Investments LP lifted its position in Kenvue by 2.8% during the third quarter. Versor Investments LP now owns 26,016 shares of the company’s stock worth $422,000 after acquiring an additional 716 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $18.17 on Wednesday. The firm has a 50 day simple moving average of $17.78 and a 200 day simple moving average of $17.46. The company has a market cap of $34.83 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 4.33 and a beta of 0.51. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.05. The company had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.Kenvue’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $0.26 EPS. Research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.6%. The ex-dividend date was Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent research reports. Barclays increased their target price on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Citigroup boosted their target price on shares of Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group lifted their price objective on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $19.50.

Insider Buying and Selling

In other Kenvue news, Director Jeffrey C. Smith bought 3,200,000 shares of Kenvue stock in a transaction on Friday, December 12th. The shares were purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. The trade was a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.